Correction for: A set of NF-kB-regulated microRNAs induces acquired TRAIL resistance in Lung cancer (Proceedings of the National Academy of Sciences of the United States of America (2015) 112 (E3355-E3364) DOI: 10.1073/pnas.1504630112);A set of NF-κB - Regulated microRNAs induces acquired TRAIL resistance in lung cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 26, 2015, Pages E3355-E3364

  Jeon, Young Jun ^a   Middleton, Justin ^a   Kim, Taewan ^a,b   Laganà, Alessandro ^a   Piovan, Claudia ^a,c   Secchiero, Paola ^d   Nuovo, Gerard J ^a   Cui, Ri ^a   Joshi, Pooja ^a   Romano, Giulia ^a   Di Leva, Gianpiero ^a   Lee, Bum Kyu ^e   Sun, Hui Lung ^a   Kim, Yonghwan ^f   Fadda, Paolo ^a   Alder, Hansjuerg ^a   Garofalo, Michela ^g   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f Sookmyung Women's University   (South Korea)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Acquired TRAIL resistance; Lung cancer; MicroRNAs

Indexed keywords

BCL2 RELATED PROTEIN A1; BIRC2 PROTIEN; CASPASE 3; CASPASE 8; FLICE INHIBITORY PROTEIN; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 100; MICRORNA 21; MICRORNA 30C; PROTEIN; PROTEIN KINASE B; PROTEIN MCL 1; SYNAPSIN I; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 7; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UVOMORULIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER RESISTANCE; CLINICAL PRACTICE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEGRADATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LONG TERM EXPOSURE; LUNG CANCER; MOUSE; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING; DRUG RESISTANCE; GENETIC TRANSCRIPTION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICRORNAS; NF-KAPPA B; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC;

EID: 84937134968     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1701795114     Document Type: Erratum

References (50)

1. Ashkenazi A, Dixit VM (1998) Death receptors: Signaling and modulation. Science 281(5381):1305-1308.
2. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5(11):876-885.
3. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8(10):782-798.
4. Wakelee HA, et al. (2010) Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 21(2):376-381.
5. Herbst RS, et al. (2010) A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16(23):5883-5891.
6. Herbst RS, et al. (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28(17):2839-2846.
7. Plantivaux A, Szegezdi E, Samali A, Egan L (2009) Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance? Ann N Y Acad Sci 1171:38-49.
8. Spierings DC, et al. (2003) Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9(9):3397-3405.
9. Wang X, et al. (2008) Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 7(5):1156-1163.
10. Meylan E, Tschopp J (2005) The RIP kinases: Crucial integrators of cellular stress. Trends Biochem Sci 30(3):151-159.
11. Christofferson DE, Li Y, Yuan J (2014) Control of life-or-death decisions by RIP1 kinase. Annu Rev Physiol 76:129-150.
12. Chaudhary PM, et al. (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7(6):821-830.
13. Lin Y, Devin A, Rodriguez Y, Liu ZG (1999) Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 13(19):2514-2526.
14. Lin Y, et al. (2000) The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 20(18):6638-6645.
15. Kelliher MA, et al. (1998) The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8(3):297-303.
16. Garofalo M, et al. (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16(6):498-509.
17. Sarkar FH, Li Y, Wang Z, Kong D, Ali S (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 13(3):57-66.
18. Zotti T, et al. (2011) TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and p65/RelA protein and represses NF-kappaB activation. J Biol Chem 286(26):22924-22933.
19. Chiacchiera F, Simone C (2010) The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 9(6):1091-1096.
20. Bassères DS, Baldwin AS (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25(51):6817-6830.
21. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441(7092):431-436.
22. Hall MA, Cleveland JL (2007) Clearing the TRAIL for cancer therapy. Cancer Cell 12(1):4-6.
23. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr (1998) NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281(5383):1680-1683.
24. Chen X, Kandasamy K, Srivastava RK (2003) Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 63(5):1059-1066.
25. Sheridan JP, et al. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277(5327):818-821.
26. Ricci MS, et al. (2007) Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12(1):66-80.
27. Liu H, et al. (2014) Regulation of Mcl-1 by constitutive activation of NF-κB contributes to cell viability in human esophageal squamous cell carcinoma cells. BMC Cancer 14:98.
28. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J (2001) NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 21(16):5299-5305.
29. Panner A, James CD, Berger MS, Pieper RO (2005) mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25(20):8809-8823.
30. Kim JY, et al. (2011) TRADD is critical for resistance to TRAIL-induced cell death through NF-κB activation. FEBS Lett 585(14):2144-2150.
31. Dan HC, et al. (2008) Akt-dependent regulation of NF-kappaB is controlled by mTOR and Raptor in association with IKK. Genes Dev 22(11):1490-1500.
32. Meng F, Liu L, Chin PC, D'Mello SR (2002) Akt is a downstream target of NF-kappa B. J Biol Chem 277(33):29674-29680.
33. Varfolomeev E, et al. (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280(49):40599-40608.
34. McConkey DJ, et al. (2009) Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28(3-4):335-344.
35. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627.
36. Dimberg LY, et al. (2013) On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32(11):1341-1350.
37. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161(6):2833-2840.
38. Jin Z, McDonald ER, 3rd, Dicker DT, El-Deiry WS (2004) Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279(34):35829-35839.
39. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M (2001) Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 61(6):2704-2712.
40. Garofalo M, et al. (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18(1):74-82.
41. Yanaihara N, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3):189-198.
42. Hatley ME, et al. (2010) Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18(3):282-293.
43. Wang T, et al. (2012) Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS ONE 7(8):e43268.
44. Grunert M, et al. (2012) The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL. Cell Death Dis 3:e414.
45. Schneider P, et al. (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7(6):831-836.
46. Jun JI, et al. (2005) Role of FLASH in caspase-8-mediated activation of NF-kappaB: dominant-negative function of FLASH mutant in NF-kappaB signaling pathway. Oncogene 24(4):688-696.
47. Rébé C, et al. (2007) Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. Blood 109(4):1442-1450.
48. Kumar M, et al. (2013) NF-κB regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells. PLoS ONE 8(7):e68597.
49. Xue W, et al. (2011) Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 1(3):236-247.
50. Nuovo GJ, et al. (2009) A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat Protoc 4(1):107-115.